Cat veterinary drug interaction evidence
Published: · Updated:
Verified direct-evidence drug-interaction rules scoped to cat, with source citations and species-specific limits.
What does ZooDDI mean by cat evidence?
This page includes only rules whose species field resolves to cat, whose catalogue status is verified, whose inference type is direct and whose evidence contains a citation.
Which verified direct-evidence rules mention cat?
The catalogue contains 9 qualifying rule records for cat, involving acepromazine, carbimazole, ciclosporin a, ivermectin, ketoconazole, metoclopramide, phenobarbital.
Can evidence for this species be applied to another species?
No. Species-specific evidence must not be silently transferred to another animal. Cross-species signals are described separately and are not direct evidence for this page.
Does no matching interaction rule prove safety?
No. A missing rule means the current published catalogue returned no qualifying match. It does not prove safety, compatibility or an appropriate dose.
What counts as direct evidence here?
Direct evidence here means a cited rule with explicit species scope, verified catalogue status and direct inference type. A product-label warning is not automatically a controlled interaction study. These fields do not establish independent expert review, an effect size, incidence or a patient-specific dose.
Published rule summary
Matching records are grouped by combination, species, recorded conditions, severity, role and displayed source context. Counts describe catalogue records, not independent studies. The context column reproduces recorded official-label wording where available. Severity and role are stored catalogue classifications; review the cited label for clinical interpretation.
| Combination | Species | Recorded conditions | Catalogue severity / role | Source context | Sources |
|---|---|---|---|---|---|
| carbimazole + phenobarbital | cat | carbimazole: formulation tablet | moderate / risk interaction | Concomitant treatment with phenobarbital may reduce the clinical efficacy of carbimazole. | [5] [6] |
| ciclosporin a + ivermectin | cat | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [4] |
| ciclosporin a + ketoconazole | cat | ciclosporin a: route oral | moderate / risk interaction | The compound class of azoles (e.g. ketoconazole) is known to increase the blood concentration of ciclosporin in cats and dogs, which is considered to be clinically relevant. | [3] |
| ciclosporin a + ketoconazole | cat | ciclosporin a: route oral | moderate / risk interaction | The compound class of azoles (e.g. ketoconazole) is known to increase the blood concentration of ciclosporin in dogs and cats, which is considered to be clinically relevant. | [4] |
| ciclosporin a + macrocyclic lactones (drug class) | cat | ciclosporin a: route oral | major / risk interaction | Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity. | [4] |
| metoclopramide + acepromazine | cat | metoclopramide: route oral | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [7] |
| metoclopramide + acepromazine | cat | metoclopramide: route subcutaneous | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derivated from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [2] |
| metoclopramide + acepromazine | cat | metoclopramide: route subcutaneous | moderate / risk interaction | Concurrent use of metoclopramide with neuroleptics derived from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see section 4.6). | [1] |
Evidence sources
These citations are source records, not a count of independent clinical studies. Repeated product labels or editions may carry the same warning.
- official_label
VMD PID:A008831, Metomotyl 5 mg/ml Solution for Injection for Cats and Dogs, version b33134733a18a6a44b42fddbfb805c4f · Open source
- official_label
VMD PID:A007821, Emeprid 5 mg/ml Solution for Injection for Dogs and Cats, version ef1184581d2907f08852448a2ec86324 · Open source
- official_label
VMD PID:A008064, Atopica 100 mg/ml Oral Solution for Cats and Dogs, version e7dbeddf99572d9277954c57896f910c · Open source
- official_label
VMD PID:A008769, Cyclavance 100 mg/ml Oral Solution for Dogs and Cats, version b59ab7b8c5e0b1b5d90f3d50388ab5d4 · Open source
- official_label
VMD PID:A012852, Felinta 10 mg Prolonged-release Tablets for Cats, version d7f0f2c33f62d9c886b5692303ec787f · Open source
- official_label
VMD PID:A012853, Felinta 15 mg Prolonged-release Tablets for Cats, version 8046d3ebb20377bb46ff70185546d317 · Open source
- official_label
VMD PID:A007820, Emeprid 1 mg/ml Oral Solution for Dogs and Cats, version cf981f88566c484881bc6313c2dea313 · Open source
Verified drug pages for this species
These links point only to published pages with their own verified direct-evidence records.
Content responsibility: ZooDDI. This is a source-linked reference for veterinary review, not a diagnosis, prescription or emergency service.